MuSK antibody clearance during serial sessions of plasmapheresis for myasthenia gravis

Jiann Horng Yeh, Wei Hung Chen, Hou Chang Chiu, Chyi Huey Bai

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

To evaluate the relationship of antibody clearance and clinical improvement for myasthenia gravis (MG) patients with MuSK antibody (MuSKAb) receiving one course of double-filtration plasmapheresis (DFP) treatment, we prospectively recorded their MG scores and measured MuSKAb concentrations before and after each DFP treatment session in two MuSKAb-positive patients. The clinical improvement trends roughly paralleled the reductions of MG score, except for the late rebound of MuSKAb in the 6th DFP treatment session, without concomitant clinical worsening in one patient. Longitudinal analysis on the serological changes during the serial sessions revealed that the levels of MuSKAb fell by 44%, 59%, 79%, 82%, 92%, and 71% in patient 1 and 52%, 70%, 78%, 87%, and 90% in patient 2. The titers of MuSKAb decreased constantly during the first 5 DFP treatment sessions. MuSKAb clearance per session for the 11 sessions ranged from 19% to 56%, with a mean of 45%. In conclusion, DFP was effective for MuSKAb removal and amelioration of clinical weakness for our two patients with MuSKAb. A 5-session protocol cleared 90% of serum MuSKAb.

Original languageEnglish
Pages (from-to)191-193
Number of pages3
JournalJournal of the Neurological Sciences
Volume263
Issue number1-2
DOIs
Publication statusPublished - Dec 15 2007
Externally publishedYes

Fingerprint

Plasmapheresis
Myasthenia Gravis
Antibodies
Therapeutics

Keywords

  • Clearance rate
  • Double-filtration plasmapheresis
  • MuSK antibody
  • Plasma exchange
  • Seronegative myasthenia gravis

ASJC Scopus subject areas

  • Ageing
  • Clinical Neurology
  • Surgery
  • Developmental Neuroscience
  • Neurology
  • Neuroscience(all)

Cite this

MuSK antibody clearance during serial sessions of plasmapheresis for myasthenia gravis. / Yeh, Jiann Horng; Chen, Wei Hung; Chiu, Hou Chang; Bai, Chyi Huey.

In: Journal of the Neurological Sciences, Vol. 263, No. 1-2, 15.12.2007, p. 191-193.

Research output: Contribution to journalArticle

Yeh, Jiann Horng ; Chen, Wei Hung ; Chiu, Hou Chang ; Bai, Chyi Huey. / MuSK antibody clearance during serial sessions of plasmapheresis for myasthenia gravis. In: Journal of the Neurological Sciences. 2007 ; Vol. 263, No. 1-2. pp. 191-193.
@article{239bd8eb4b3b4b2d879b95b7534e0c13,
title = "MuSK antibody clearance during serial sessions of plasmapheresis for myasthenia gravis",
abstract = "To evaluate the relationship of antibody clearance and clinical improvement for myasthenia gravis (MG) patients with MuSK antibody (MuSKAb) receiving one course of double-filtration plasmapheresis (DFP) treatment, we prospectively recorded their MG scores and measured MuSKAb concentrations before and after each DFP treatment session in two MuSKAb-positive patients. The clinical improvement trends roughly paralleled the reductions of MG score, except for the late rebound of MuSKAb in the 6th DFP treatment session, without concomitant clinical worsening in one patient. Longitudinal analysis on the serological changes during the serial sessions revealed that the levels of MuSKAb fell by 44{\%}, 59{\%}, 79{\%}, 82{\%}, 92{\%}, and 71{\%} in patient 1 and 52{\%}, 70{\%}, 78{\%}, 87{\%}, and 90{\%} in patient 2. The titers of MuSKAb decreased constantly during the first 5 DFP treatment sessions. MuSKAb clearance per session for the 11 sessions ranged from 19{\%} to 56{\%}, with a mean of 45{\%}. In conclusion, DFP was effective for MuSKAb removal and amelioration of clinical weakness for our two patients with MuSKAb. A 5-session protocol cleared 90{\%} of serum MuSKAb.",
keywords = "Clearance rate, Double-filtration plasmapheresis, MuSK antibody, Plasma exchange, Seronegative myasthenia gravis",
author = "Yeh, {Jiann Horng} and Chen, {Wei Hung} and Chiu, {Hou Chang} and Bai, {Chyi Huey}",
year = "2007",
month = "12",
day = "15",
doi = "10.1016/j.jns.2007.05.033",
language = "English",
volume = "263",
pages = "191--193",
journal = "Journal of the Neurological Sciences",
issn = "0022-510X",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - MuSK antibody clearance during serial sessions of plasmapheresis for myasthenia gravis

AU - Yeh, Jiann Horng

AU - Chen, Wei Hung

AU - Chiu, Hou Chang

AU - Bai, Chyi Huey

PY - 2007/12/15

Y1 - 2007/12/15

N2 - To evaluate the relationship of antibody clearance and clinical improvement for myasthenia gravis (MG) patients with MuSK antibody (MuSKAb) receiving one course of double-filtration plasmapheresis (DFP) treatment, we prospectively recorded their MG scores and measured MuSKAb concentrations before and after each DFP treatment session in two MuSKAb-positive patients. The clinical improvement trends roughly paralleled the reductions of MG score, except for the late rebound of MuSKAb in the 6th DFP treatment session, without concomitant clinical worsening in one patient. Longitudinal analysis on the serological changes during the serial sessions revealed that the levels of MuSKAb fell by 44%, 59%, 79%, 82%, 92%, and 71% in patient 1 and 52%, 70%, 78%, 87%, and 90% in patient 2. The titers of MuSKAb decreased constantly during the first 5 DFP treatment sessions. MuSKAb clearance per session for the 11 sessions ranged from 19% to 56%, with a mean of 45%. In conclusion, DFP was effective for MuSKAb removal and amelioration of clinical weakness for our two patients with MuSKAb. A 5-session protocol cleared 90% of serum MuSKAb.

AB - To evaluate the relationship of antibody clearance and clinical improvement for myasthenia gravis (MG) patients with MuSK antibody (MuSKAb) receiving one course of double-filtration plasmapheresis (DFP) treatment, we prospectively recorded their MG scores and measured MuSKAb concentrations before and after each DFP treatment session in two MuSKAb-positive patients. The clinical improvement trends roughly paralleled the reductions of MG score, except for the late rebound of MuSKAb in the 6th DFP treatment session, without concomitant clinical worsening in one patient. Longitudinal analysis on the serological changes during the serial sessions revealed that the levels of MuSKAb fell by 44%, 59%, 79%, 82%, 92%, and 71% in patient 1 and 52%, 70%, 78%, 87%, and 90% in patient 2. The titers of MuSKAb decreased constantly during the first 5 DFP treatment sessions. MuSKAb clearance per session for the 11 sessions ranged from 19% to 56%, with a mean of 45%. In conclusion, DFP was effective for MuSKAb removal and amelioration of clinical weakness for our two patients with MuSKAb. A 5-session protocol cleared 90% of serum MuSKAb.

KW - Clearance rate

KW - Double-filtration plasmapheresis

KW - MuSK antibody

KW - Plasma exchange

KW - Seronegative myasthenia gravis

UR - http://www.scopus.com/inward/record.url?scp=35649022743&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35649022743&partnerID=8YFLogxK

U2 - 10.1016/j.jns.2007.05.033

DO - 10.1016/j.jns.2007.05.033

M3 - Article

C2 - 17602704

AN - SCOPUS:35649022743

VL - 263

SP - 191

EP - 193

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

SN - 0022-510X

IS - 1-2

ER -